Xiaflex
(Collagenase clostridium histolyticum)ApprovedSmall molecule
Xiaflex is used to break down and dissolve excess collagen buildup in conditions like Dupuytren's contracture (a hand deformity where fingers curl inward) and Peyronie's disease (curved penis caused by scar tissue). The enzyme works by digesting the problematic scar tissue to improve function and appearance.[2] Xiaflex is currently approved and in use across 12 indications[4].[1]
Xiaflex is one of 134 small molecule programs targeting Palmar Fibromatosis. It is currently in Approved.
12
Indications
26
Total Trials
5
Active Trials
133
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
149 competitors in Safety and Efficacy
#DrugCompanyPhaseTrials
1Xiaflex
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Rituxan
RochePhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Humira
NovartisPhase 3
Avastin
RochePhase 3
BEYFORTUS
SanofiPhase 3
Adriamycin
PfizerPhase 3
Oncovin
Eli LillyPhase 3
Neulasta
AmgenPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment5 trials
Dupuytren's Disease4 trials
Contracture4 trials
Effectiveness3 trials
Peyronie's Disease2 trials
Comparison of Collagenase Clostridium Histolyticum to Surgery for the Management of Peyronie's Disease: A Randomized Trial
Active, not recruiting·CCharitable Union for the Research and Education of Peyronie's Disease·Approved·NCT04786106·40 enrolled
8 more indications
Lipoma1 trial
Adhesive Capsulitis of the Shoulder1 trial
Plantar Fasciitis1 trial
Safety and Efficacy1 trial
Erectile Dysfunction1 trial
Double-blind1 trial
Peyronie disease1 trial
Efficacy of a Step-wise Protocol in Optimizing CCH Outcomes in Men With Peyronie's Disease
Active, not recruiting·CCharitable Union for the Research and Education of Peyronie's Disease·Approved·NCT06649539·40 enrolled
Regulatory
FDA Approval Timeline[5]
Feb 2, 2010
XIAFLEX
BLA BLA125338
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Xiaflex drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]
- [5]
- [6]
Details